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Blockade of Angio-Associated Migratory
Cell Protein Inhibits Smooth Muscle Cell Migration
and Neointima Formation in Accelerated Atherosclerosis
Felix Vogt, MD,* Alma Zernecke, MD,‡ Marie Beckner, PHD,§ Nicole Krott, MSC,*†
Anja-Katrin Bosserhoff, PHD, Rainer Hoffmann, MD,* Marc A. M. J. Zandvoort, PHD,#
Thomas Jahnke, MD,¶ Malte Kelm, MD,* Christian Weber, MD,‡ Rüdiger Blindt, MD*
Aachen, Regensburg, and Campus Kiel, Germany; Pittsburgh, Pennsylvania; and Maastricht, the Netherlands
Objectives The aim of this study was to elucidate the role of angio-associated migratory cell protein (AAMP) for the migration of
vascular smooth muscle cells (SMCs) and for the development of neointimal hyperplasia after vascular injury.
Background Although AAMP has been shown to participate in angiogenesis and cancerogenesis and is predominantly
expressed in cells with a migratory phenotype, involvement of AAMP during neointima (NI) formation after arte-
rial injury has not been analyzed previously.
Methods The AAMP content in SMCs was examined using 2-photon laser-scanning microscopy and subcellular fractioning.
Migratory potential of SMCs transiently transfected with AAMP expression vectors, transfected with small inter-
fering ribonucleic acid (siRNA), or treated with antirecombinant angio-associated migratory cell protein–antibody
(anti-rAAMP-ab) was examined using transwell migration chamber assays. Expression of AAMP was determined
in the atherogenic apolipoprotein E knockout (apoE/) mouse model and in the porcine coronary restenosis
model by immunohistochemistry and by Western blot. ApoE/ mice were treated intraperitoneally with anti-
rAAMP-ab, and wire-injured carotid arteries were examined.
Results Angio-associated migratory cell protein is localized in the membrane of SMCs, and its expression is enhanced in
NI-derived SMCs. The AAMP overexpression increases, while both treatment with anti-rAAMP-ab and transfection
with siRNA decreases SMC migration. Knockdown of AAMP decreases RhoA activity in the membrane fraction of
SMCs. The AAMP expression by SMCs is enhanced in both animal models. Anti-rAAMP-ab reduces neointimal
SMC density at 1 week and NI formation at 4 weeks in apoE/ mice without affecting proliferation of SMCs.
Conclusions These data reveal an important functional role of AAMP in the migration of SMCs, identifying AAMP as a poten-
tial target to limit lesion formation after injury. (J Am Coll Cardiol 2008;52:302–11) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.055m
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dngio-associated migratory cell protein (AAMP) is a re-
ently identified small protein with a molecular weight of 52
Da. It is predominantly expressed in cells with a migratory
henotype, including endothelial cells, activated T-cells,
nd glia cells, as well as in malignant tissue such as human
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Manuscript received October 1, 2007; revised manuscript received February 4,
008, accepted March 4, 2008.elanoma cells and adenocarcinoma cells of the colon.
hus, a role in angiogenesis and cancerogenesis was pre-
umed (1,2). Angio-associated migratory cell protein shares
equence homology with immunoglobulin superfamily
embers, including cellular adhesion molecules such as neural
ell adhesion molecule (NCAM), platelet-endothelial cell
dhesion molecule (PECAM), and leukocyte function
ntigen-2 (LFA-2); these and other immunoglobulin su-
erfamily proteins mediate adhesion and migration of var-
ous malignant circulating cells (1,3).
See page 312
Migration of smooth muscle cells (SMCs) into the
eveloping neointima (NI) is a pivotal step during athero-
clerosis development in native vessels as well as in reste-
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July 22, 2008:302–11 AAMP and Accelerated Atherosclerosisosis formation after vascular intervention. After injury, a
witch of the SMC phenotype from the quiescent to the
ecretory phenotype is followed by SMC migration and
roduction of extracellular matrix in the NI (4,5). During
ttachment and migration, SMCs polarize and extend
rotrusions in the direction of migration. These microex-
ensions are driven by actin polymerization, representing a
ynamic reorganization of the actin cytoskeleton. The regula-
ory mechanisms of actin restructuring remain unclear, but a
omplex interaction of actin-cytoskeletal associated proteins
ith GTPases might contribute (6). These processes possibly
nduce a change from a quiescent to a migratory SMC
henotype (7,8). Various mediators such as interleukins or
latelet-derived growth factor—which can be secreted from
latelets, monocytes, or SMCs—can trigger the migration of
MCs (9). The expression of AAMP by SMCs during
therosclerosis and restenosis development, however, has not
een studied previously. Thus, the rationale of this study was to
lucidate the role of AAMP for the migration of SMCs and
or the development of neointimal hyperplasia after vascular
njury. To explore this, we quantified AAMP expression in
MCs derived from the NI and media as well as in athero-
clerotic lesions of apolipoprotein E knockout (apoE/) mice
nd restenotic lesions of porcine coronary arteries. Further-
ore, the subcellular localization of AAMP and its effects on
MC migration and proliferation were analyzed. Eventually,
e evaluated the in vivo expression of AAMP in the non-
therogenic porcine model of coronary balloon dilation and in
he atherogenic mouse model of accelerated lesion formation.
he effect of AAMP blockade on NI formation as well as
MC migration and proliferation was tested by treatment of
ire-injured apoE/mice with an inhibitory antibody against
AMP.
ethods
ulture of SMCs. Medial rat smooth muscle cells
rSMCs) were isolated from the medial layer of the thoracic
orta of 6-week-old male Sprague-Dawley rats; neointimal
SMCs were derived from the neointimal thickening of the
orta 2 weeks after balloon angioplasty by microscopic
issection (10). Human smooth muscle cells (hSMCs) were
solated from the medial layer of mammary arteries after
oronary artery bypass operation as described (11); informed
ritten consent of all patients was obtained before the
rocedure. The SMCs were sparsely and densely grown and
onsecutively tested for their migratory potential with a
ranswell migration chamber system as previously described
11). Only SMCs with a distinct migratory phenotype were
sed for migration experiments; dense-grown SMCs, char-
cterized by a significantly lower migratory potential, served
s negative control.
ntibodies. An affinity-purified polyclonal antibody
gainst recombinant AAMP was generated in rabbits
anti-rAAMP-ab; concentration 1 g/ml) (1) and was
sed for detection of AAMP by Western blotting and smmunohistochemistry. Due to
ts inhibitory capacity (12), the
ntibody was used for transwell
igration chamber assays and
or intraperitoneal administra-
ion in mice. Nonimmune rabbit
mmunoglobulin G serum (Sigma-
ldrich, St. Louis, Missouri)
erved as negative control. For
etection, an alkaline phospha-
ase coupled secondary antibody
anti-rabbit, Chemicon, Temecula,
alifornia) was used. Antibody
taining by monoclonal antibod-
es against alpha-smooth muscle
ctin (SMA) (Dako, Glostrup,
enmark), beta-actin (Sigma-
ldrich), von Willebrand factor
Dako), RhoA (Santa Cruz Bio-
echnology, Santa Cruz, Califor-
ia), and Ki67 (Dako) was de-
ected by a secondary horseradish
eroxidase-labeled antibody from
ako. For AAMP fluorescence
taining, a fluorescein isothiocyanate (FITC)-conjugated
ntirabbit antibody was used (Chemicon).
luorescence staining, 2-photon laser-scanning micros-
opy, and flow cytometric analysis. The rSMCs and
SMCs grown on glass slides were washed in phosphate
uffered saline (PBS), fixed immediately with 3.7% formal-
ehyde/PBS for 5 min, dehydrated by immersion in ace-
one, and permeabilized with 0.1% Triton X-100. Cells
ere stained with anti-rAAMP-ab and the respective
ITC-conjugated antibody. After nuclear staining with
API (4=,6-diamidino-2-phenylindole, Sigma-Aldrich),
lides were analyzed by 2-photon laser-scanning microscopy
sing a Nikon Eclipse E600FN upright microscope (Tokyo,
apan), incorporated in the Bio-Rad Radiance 2100MP
maging system, and operated by Lasersharp2000 V6.0
Bio-Rad, Hemel Hempstead, United Kingdom). Excita-
ion was by the Tsunami Ti:sapphire laser (Spectra-Physics,
ountain View, California). Slides were observed through
water dipping 60 fluor objective with a 1.00 numerical
perture (Nikon, Tokyo, Japan) (13).
Flow cytometric analysis was performed as previously
escribed (14). Cells were detached with accutase and
ubjected to flow cytometric analysis with or without
ween-induced membrane permeabilization and stained
ith anti-rAAMP-ab and the respective FITC-conjugated
ntibody. An FITC-conjugated immunoglobulin G isotype
erved as negative control.
uantitative Western blotting. For Western blotting
f cultured SMCs, cells were suspended in radio-
mmunoprecipitation assay buffer (Roche, Mannheim, Ger-
any); for analysis of SMC supernatants, concentration of
Abbreviations
and Acronyms
AAMP  angio-associated
migratory cell protein
anti-rAAMP-ab 
recombinant angio-
associated migratory cell
protein–antibody
apoE/  apolipoprotein
E knockout
FITC  fluorescein
isothiocyanate
GFP  green fluorescent
protein
hSMC  human smooth
muscle cell
NI  neointima
rSMC  rat smooth muscle
cell
siRNA  small interfering
ribonucleic acid
SMA  smooth muscle
actinupernatants was performed by freeze drying (Christ Alpha
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AAMP and Accelerated Atherosclerosis July 22, 2008:302–11-4, Braun Biotech Int., Melsungen, Germany) before
estern blotting. For in vivo expression analysis, porcine
oronary arteries were prepared as previously described
15,16). Always, 15 g of protein was used. Equal loading
f Western blots was assured by quantification of total
rotein content before each experiment (BCA Protein
ssay Kit, Pierce, Rockford, Illinois) and by assessment of
eta-actin expression. Blotted membranes were quantified
ith “ImageJ” image processing software (17).
ubcellular fractioning and RhoA and Rac activity as-
ays. To explore differential AAMP and RhoA localization
y subcellular fractioning, a proteome extraction kit (Merck
hemicals, Nottingham, United Kingdom) was applied as
escribed by the manufacturer. Membrane fractions that
ontain activated guanosine triphosphate-bound RhoA
nd cytosolic fractions that contain inactive guanosine
iphosphate-bound RhoA were analyzed by Western blot-
ing. For Rac analysis, a Rac activation assay kit (Upstate,
ake Placid, New York) was applied according to the
anufacturer’s instructions.
omputed AAMP sequence analysis. Searching for po-
ential transmembrane domains was performed by com-
uted AAMP sequence analysis (DNAMAN software,
ynnon BioSoft, Quebec City, Canada).
ransient transfection of AAMP vector constructs and
mall interfering ribonucleic acid (siRNA). The AAMP
omplementary deoxyribonucleic acid was inserted into the
ector pCMX-GL1 via EcoRI restriction sites. Mock and
reen fluorescent protein (GFP) vectors were used as
ontrols. To induce AAMP knockdown in SMCs, siRNA
as used. The AAMP siRNA, lamin controls, and fluo
uplex transfection efficacy controls were purchased from
harmacon (Lafayette, Colorado).
For transfection of AAMP vectors and siRNA, 3  105
ells were seeded into T25 plates for functional assays or
 104 cells were seeded into each well of a 6-well plate for
rotein assays. The Amaxa NucleofectorTM technology
Amaxa, Cologne, Germany) was used for transfection of
MCs as previously described (11).
hemotaxis assays and proliferation analysis. For che-
otaxis experiments, transwell migration chambers were
sed (Neuro Probe Inc., Gaithersburg, Maryland). Polycar-
onate filters (13 mm diameter, 8 m pore size; Whatman
nternational Ltd., Kent, United Kingdom) were coated
ith gelatine (5 mg/ml) as previously described (11). The
pper compartment was filled with Dulbecco’s modified
agle’s medium with or without anti-rAAMP-ab (100
g/ml) (15). The rSMCs (2  105 cells/ml) were placed in
he upper compartment of the chamber and incubated for
h at 37°C. Transmigrated cells adhering to the lower
hamber surface were fixed, stained, and counted (Leica
M RX microscope, Wetzlar, Germany).
For proliferation analysis, a 5-bromodeoxyuridine (BrdU)
ell proliferation assay from Chemicon was applied accord-
ng to the manufacturer’s instructions. pnimal models. All animal study protocols were approved
y the local Institutional Animal Care and Use Committee
nd conformed to the tenets of the American Heart Asso-
iation on research animal use.
therogenic mouse model of accelerated atherosclerosis.
n atherogenic mouse model of accelerated lesion forma-
ion was applied as previously described (18). In brief, a
.014-inch flexible angioplasty guide wire was advanced
nto the carotid artery of apoE/ mice (C57BL/6 back-
round, M&B, Ry, Denmark) via an incision in the external
arotid artery, and endothelial denudation was achieved by
rotary passes along the common carotid artery.
After intraperitoneal administration of anti-rAAMP-ab
t different concentrations, serum concentration of anti-
AAMP-ab was determined by dot blot reactions at 24, 48,
nd 72 h. At 72 h, an anti-rAAMP-ab serum concentration
f 2 g/ml was achieved after application of 50 g anti-
AAMP-ab/animal. Subsequently, apoE/ mice were in-
raperitoneally treated with 50 g anti-AAMP-ab or con-
rol nonimmune serum (n  9 each) every 72 h starting 1
eek before and up to 4 weeks after injury. One week
n  3) or 4 weeks (n  6) after injury, the animals were
illed and the arteries were perfusion-fixed with 4% para-
ormaldehyde and embedded in paraffin.
orcine model of balloon-induced coronary resteno-
is. A porcine restenosis model after coronary arterial injury
as performed as previously described (15,16). Briefly, after
stablishing arterial access by Doppler guided puncture of
he femoral artery, 7,500 IU heparin were administered and
he left anterior descending coronary artery was engaged
ith a 6-F guiding catheter. After intracoronary adminis-
ration of nitrate (0.1 mg), the vessel diameter was calcu-
ated online by quantitative coronary angiography. The
alloon/artery ratio was 1.1 to 1.2. The noninstrumented
eft circumflex artery served as uninjured control. Angio-
lasty was performed in a total of 6 animals by balloon
nflation for 2  30 s (10 to 12 atm). Animals were
aintained on a normal laboratory diet until being killed at
week (n  6) or 4 weeks (n  6). Hearts were harvested,
nd the epicardial coronary arteries were removed.
istomorphometrical and histopathological evaluation.
or histomorphometrical evaluation of murine arteries,
odified Movat’s pentachrome stainings were performed on
araffin-embedded sections as previously described (17). For
istopathological evaluation, cell nuclei were counterstained
ith Mayer’s hemalaun (Merck, Darmstadt, Germany).
he AAMP expression intensity in SMCs was quantified
y pixel analysis of AAMP staining intensity (Vectastain
BC-AP, Vector Laboratories, Burlingame, California).
esults were expressed as cumulative intensity divided by
otal SMC area. Total AAMP or -SMA vessel wall
rea of the media and NI was quantified and expressed as
ositive area percentage.
For proliferation analyses, Ki67-positive cell nuclei were
ounted, divided by total cell numbers, and displayed as
ercentage index of cell proliferation. Tissue sections from
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July 22, 2008:302–11 AAMP and Accelerated Atherosclerosishe proximal, mid, and distal part of the injured vessel
egment were analyzed as previously described (15–17).
issue analysis was performed on digitized images (Leica
M RX microscope; “Diskus” analysis software, version
.30, Hilgers, Koenigswinter, Germany) (15); for pixel
nalysis, “ImageJ” image processing software was applied.
tatistical analysis. All results are expressed as mean 
EM. For in vitro experiments, statistical significance was
valuated with the unpaired Student t test or analysis of
ariance, followed by Dunnett’s post hoc test for more than
means. For histomorphometric measurements, the
ruskal-Wallis test was used to determine overall statistical
ignificance, followed by the Mann-Whitney U test with
onferroni correction for subsequent pairwise comparison if
he overall significance was 0.05; p values 0.05 were
onsidered significant.
esults
ubcellular localization of AAMP. In sparsely grown
SMCs, AAMP expression was enhanced and preferen-
ially localized along the cell membrane, whereas only weak
taining for AAMP was detected in dense hSMCs and
edial rSMCs (Fig. 1A), implying a phenotype-related
hange in localization and strength of expression. Subcel-
ular fractioning of hSMCs confirmed that AAMP is
ocated primarily at the cellular membrane (55.5  4.4
ntensity/area) but also in the cytosolic fraction (23.1  3.9;
 0.01), whereas the nuclear fraction did not contain
AMP (0.2  0.1; p  0.001) (Fig. 1B). Flow cytometric
nalysis of hSMCs also demonstrated that AAMP is
resented preferentially at the cell membrane (without
ween treatment: 1,906  185 FITC-A intensity) but
an also be found in the cytosol (permeabilized cells with
ween treatment: 3,967  203; nonimmune control: 345
25; p  0.01) (Fig. 1C). Accordingly, computed analysis
f AAMP sequence revealed a potential transmembrane do-
ain between amino acids 322 and 345 (Fig. 1D).
AMP expression by SMCs. In medial sparse-grown
SMCs, AAMP expression was significantly increased
ompared with dense-grown medial hSMCs (33.3  4.0
nd 11.2  3.3 intensity/area, p  0.01). Similarly, sparse
edial rSMCs displayed significantly higher AAMP levels
ompared with dense medial rSMCs (64.9  6.0 and 21.4
4.1, p  0.01). Both, sparse and dense rSMCs derived
rom the NI displayed a pronounced AAMP expression
72.5  6.1 and 66.2  7.1, p  0.54), indicating that
AMP expression in neointimal cells can not be downregu-
ated (Fig. 2A).
In cellular supernatants of rSMCs as well as hSMCs,
AMP expression was very low or not detectable (data not
hown).
ffect of AAMP on SMC migration and proliferation.
reatment with the inhibitory anti-rAAMP-ab reduced
MC migration. Migration of both medial and, even more
rofoundly, neointimal rSMCs was inhibited by AAMP20 µm20 µm
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Figure 1 Expression and Subcellular Localization of AAMP
(A) Two-photon laser-scanning microscopy of sparse smooth muscle cells (left) detect-
ing intensified angio-associated migratory cell protein (AAMP) distribution (green) at the
cellular membrane (arrows), whereas dense cells (right) contain less AAMP without
distinctive distribution patterns. (B) Subcellular fractioning: the cellular membrane con-
tains 50% of total cellular AAMP; as expected by fluorescence microscopy, the cellu-
lar nuclei did not contain AAMP. (C) Flow cytometric analysis of AAMP expression
treated or untreated with lysis buffer confirmed the results of the subcellular fraction-
ing experiments (red: nonimmune serum, green: without Tween, blue: with Tween). (D)
Computed AAMP protein sequence analysis revealed a potential transmembrane
domain between amino acids 322 and 345. FITC  fluorescein isothiocyanate.
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AAMP and Accelerated Atherosclerosis July 22, 2008:302–11Figure 2 Phenotype-Related AAMP Expression in SMCs and the Effect of AAMP on SMC Migration
(A) Western blot analysis of angio-associated migratory cell protein (AAMP) expression in human smooth muscle cells (hSMCs) and rat smooth muscle cells (rSMCs).
(B) Blockade of AAMP by an inhibitory recombinant AAMP-antibody (anti-rAAMP-ab) reduced the migratory potential of medial and of neointimal rSMCs in modified trans-
well chambers. (C) The migratory activity of hSMCs and rSMCs after AAMP-sense vector-transfection was increased compared with controls. (D) The AAMP knockdown by
small interfering ribonucleic acid (siRNA) alleviated hSMC migration compared with controls. (E) Five-bromodeoxyuridine (BrdU) assays showed no effect of anti-rAAMP-ab
treatment, vector transfection, and siRNA treatment on SMC proliferation. GFP  green fluorescent protein.
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July 22, 2008:302–11 AAMP and Accelerated Atherosclerosislockade in comparison with control (21.5  4.0 and 74.4
11.6 cells/area vs. 49.7 3.8 and 164.5 20.6 cells/area,
espectively; p  0.001) (Fig. 2B). After transfection with
AMP expression vectors, SMCs displayed an enhanced
igratory potential compared with mock or GFP trans-
ected cells (hSMCs: 48.5  3.5, 26.3  2.7, and 27.3 
.0; p  0.01; rSMCs: 55.9  4.2, 31.2  2.4, and 34.4 
.9; p  0.01) (Fig. 2C). The AAMP vector transfection
esulted in AAMP overexpression as compared with mock
nd GFP transfected cells (hSMCs: 34.1 2.0, 13.2 2.1,
nd 16.0  2.8 intensity/area; rSMCs: 41.1  2.0, 18.0 
.0, and 17.5  2.8 intensity/area; p  0.01) (Fig. 2C).
Accordingly, AAMP knockdown by siRNA reduced the
igratory potential of hSMCs compared with untreated
nd lamin controls (24.9  2.0, 57.9  3.5, and 55.6  3.5
ells/area; p  0.01) (Fig. 2D), and the cellular AAMP
ontent was reduced compared with controls (13.1  2.2,
3.3  2.8, and 31.3  3.5 intensity/area; p  0.01) (Fig.
D). Fluo duplex transfection efficacy checks confirmed
ood transfection efficacy (data not shown).
Treatment with anti-rAAMP-ab (0.094  0.003 absor-
ance), AAMP sense-vectors (0.090  0.007), and AAMP
iRNA (0.096  0.007) did not alter hSMC proliferation
ompared with controls (untreated: 0.098  0.005; nonim-
une serum: 0.099  0.005; mock transfection: 0.095 
.008; GFP transfection: 0.087  0.002; lamin: 0.094 
.005; p  0.738) (Fig. 2E).
These data imply that AAMP is crucially involved in the
egulation of SMC migratory activity.
ellular membrane-associated AAMP regulates SMC
igration by modulation of RhoA activity. By proteome
xtraction, the effect of AAMP knockdown by siRNA was
ssessed for membrane and cytosolic hSMC fractions. The
AMP knockdown effectively reduced the membranous
AMP content (11.3  1.5 intensity/area) compared with
ntreated (24.3  2.0) and lamin controls (23.3  2.7; p 
.01) (Fig. 3A). In the cytosolic fraction, AAMP content
as not significantly altered by siRNA (14.2  2.5) com-
ared with untreated (18.5  2.0) and lamin controls (19.2
1.8; p 0.05) (Fig. 3A). The AAMP knockdown (0.5
.1) and anti-rAAMP-ab treatment (0.4  0.0) both
educed RhoA content, whereas AAMP sense-vector trans-
ection (9.1  1.0) enhanced RhoA content in the mem-
rane compared with controls (untreated: 4.6  1.2, mock:
.2  1.0, GFP: 5.4  0.9, lamin: 5.1  0.8; p  0.01)
Fig. 3B). Cytosolic RhoA content was not altered by the
ifferent treatment modalities (AAMP siRNA: 11.0  1.0;
nti-rAAMP-ab: 11.3  1.0; AAMP sense-vector: 10.2 
.0; untreated: 11.3  0.9; mock: 11.3  0.8 intensity/area;
FP: 10.2  0.9; lamin: 11.0  1.0; p  0.01) (Fig. 3B).
nalysis of Rac activation did not reveal significant differ-
nces (data not shown).
nalysis of temporal and quantitative AAMP expression
n vivo. Pixel analysis of immunofluorescence staining in
njured apoE/ mice by calculating AAMP expression
ntensity/cellular area revealed a slightly stronger expression mf AAMP in 1- and 4-week groups in the media compared
ith the uninjured group (25.3  2.8, 23.1  2.2, and 18.0
1.4 intensity/cellular area, p  0.18) (Figs. 4A and 4B),
hereas neointimal AAMP expression was significantly
ncreased at 1 and 4 weeks as compared with the media of
he same group (40.2 2.8 and 36.8 2.6, p 0.01) (Figs.
A and 4B).
Similar AAMP expression patterns were observed in
he porcine model of balloon-induced coronary restenosis
Fig. 5A). Again, pixel analysis revealed a substantial
ncrease in AAMP expression in the NI at 1 and 4 weeks
fter injury (39.1  3.1 and 35.0  2.5, p  0.01), whereas
Figure 3 RhoA Activity Is Reduced by AAMP Blockade
(A) The siRNA knockdown reduced AAMP content in the membrane fraction but
not in the cytosolic fraction. (B) The RhoA activity assay: in the membrane frac-
tion, siRNA and anti-rAAMP-ab treatment greatly reduced RhoA activity, whereas
activated RhoA expression was elevated after AAMP overexpression. In the
cytosolic fraction, expression of inactive RhoA was not affected by anti-
rAAMP-ab treatment, vector transfection, or AAMP siRNA treatment. Abbrevia-
tions as in Figure 2.edial expression of AAMP was slightly enhanced at 1 and
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AAMP and Accelerated Atherosclerosis July 22, 2008:302–11weeks compared with control (24.5 2.6, 21.9 1.9, and
7.5  1.1, p  0.22) (Fig. 5B). Sections stained with
onimmune serum showed only faint nonspecific back-
round staining. Additionally, vessel wall protein lysates of
njured and non-injured arteries were analyzed by Western
lotting and quantified by subsequent densitometry. A
ignificantly higher AAMP protein content was demon-
trated at 1 and 4 weeks (41.5  2.2 and 22.2  1.2
ntensity/area, respectively) after balloon dilation compared
ith control vessels (2.8  0.6, p  0.01) (Fig. 5C).
nalysis of AAMP/-SMA-colocalization. An AAMP/
-SMA-colocalization analysis was performed to examine
ow SMCs contribute to AAMP expression.
In the murine model, medial AAMP/-SMA double-
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Figure 4 Increased AAMP Expression in Murine
Carotid Arteries After Wire-Induced Injury
(A) Photomicrographs of angio-associated migratory cell protein (AAMP)–
stained and nonimmune serum control murine sections. (B) Respective pixel
intensity analysis. NI  neointima.ositive areas as percentage of the total medial area wereA
A
M
P
 e
xp
re
ss
io
n 
[in
te
ns
ity
/c
el
lu
la
r 
ar
ea
]
at 4 weeksat 1 weekuninjured
100 µm
AAMP nonimmune serum
100 µm
uninjured
at 4 weeks
uninjured
at 1 week
at 4 weeks
at 1 week
100 µm 100 µm
100 µm 100 µm
uninjured
10
0
A
A
M
P
 e
xp
re
ss
io
n
[in
te
ns
ity
/a
re
a]
20
30
40
50 * P<0.01
*
at 4 weeksat 1 week
*
AAMP
β-actin
 


Figure 5 Increased AAMP Expression
in Balloon-Injured Porcine Coronary Arteries
(A) Photomicrographs of angio-associated migratory cell protein (AAMP)–stained and
nonimmune serum control porcine sections. (B) Respective pixel intensity analysis.
(C) Vessel wall protein lysate analysis of AAMP-expression. NI  neointima.
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July 22, 2008:302–11 AAMP and Accelerated Atherosclerosisimilar for AAMP and -SMA in uninjured (44.0  3.6%
s. 44.4  2.9%, p  0.87) and in injured specimen (at 1
eek: 42.0  3.9% vs. 39.6  2.7%, p  0.87; at 4 weeks:
7.0  3.0% vs. 36.0  3.2%, p  0.87). Also, the
eointimal double-positive percentage area was similar
ithin the groups (at 1 week: 32.0  3.4% vs. 33.0  3.2%,
 0.82; at 4 weeks: 29.7  3.8% vs. 28.3  3.2%, p 
.82) (Figs. 6A and 6B); due to reduced neotintimal cell
ensity, absolute values for AAMP/-SMA double-positive
ercentage area were lower compared with the media.
AMP contributes to NI formation and SMC migration
ut not to proliferation after injury in apoE/ mice.
he apoE/ mice were treated with inhibitory anti-
AAMP-ab or nonimmune serum intraperitoneally. At 4
eeks after injury, neointimal hyperplasia of the carotid
rtery was significantly reduced in anti-rAAMP-ab–treated
ice compared with nonimmune serum-treated control
ice (42,100  2,800 and 78,700  3,100 m2, p  0.01),
hereas medial areas were not different (19,237  3,572 and
8,423  815 m2, p  0.86) (Figs. 7A and 7B). The
eduction in neointimal area was associated with a signifi-
ant reduction in the relative density of -SMA cells in
he NI compared with nonimmune serum-treated mice at 1
eek (23.5  3.2% and 39.6  2.7%, p  0.01) but not at
weeks (37.8  3.9% and 36.0  3.2%, p  0.73) after
njury (Figs. 7C and 7D). Neointimal cell proliferation, as
uantified by Ki67 staining, was similar in both groups at 1
anti-rAAMP-ab: 12.2  0.9%; uninjured: 12.9  1.0%,
 0.92) and at 4 weeks (anti-rAAMP-ab: 4.2  0.9%;
ninjured: 5.1 1.0%; p 0.57) (Fig. 7E). In the media of
ninjured and injured arteries, there was only minimal Ki67
taining of about 1 percentage point (data not shown).
hese data imply that neutralization of AAMP protects
rom NI remodeling by early reduction of SMC migration
nto the developing lesion.
iscussion
nitially, the expression of AAMP was described for a variety
f cell types, including endothelial cells, activated T-cells, and
alignant cells, which are all characterized by a migratory
henotype (12). In further studies, upregulation of AAMP was
bserved during cancerogenesis in gastrointestinal stromal
umors (19) and ductal carcinoma in situ of the breast (20). On
atrigel, endothelial tube formation and cell migration could
e blocked by an inhibitory AAMP antibody (12). Thus, it was
peculated that AAMP was involved in tumor formation by
upporting tumor angiogenesis (21). Although cell migration is
lso integral during the development of accelerated atheroscle-
osis and restenosis (4), data investigating the role of AAMP
re not available.
In the present study, a significant upregulation of AAMP
xpression in vascular SMCs derived from the NI and in
MCs from different atherosclerotic and restenotic animal
odels was demonstrated. Moreover, AAMP overexpression aromoted SMC migration, and blockade of AAMP by an
nhibitory antibody or by siRNA reduced the migratory activity
f vascular SMCs without affecting proliferation in vitro and in
ivo. The study elucidated that, in line with these observations,
lockade of AAMP results in a highly significant reduction of
I development in an apoE/ mouse injury model. Con-
omitantly, the blockade of AAMP generated an early sub-
tantial decrease of SMC density in the NI.
In summary, these data strongly suggest that AAMP plays
n important role for SMC migration during the development
nd progression of accelerated atherosclerosis and restenosis.
otably, this was conclusively demonstrated for the non-
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Figure 6 Colocalization of AAMP and -SMA
(A) Colocalization of AAMP and -smooth muscle actin (SMA) in wire-injured
sections of the murine model. (B) Quantification of AAMP- and -SMA-positive
areas in the murine media and NI, respectively. Abbreviations as in Figure 4.therogenic porcine restenotic model and the atherogenic
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mportance, because both models are characterized by different
trengths and weaknesses. The pathophysiologic mechanisms
f neointimal development in the porcine coronary model are
ost similar to restenotic lesions in humans, but the model has
nonatherogenic background. The atherogenic mouse model
vercomes this limitation, but the character of the restenotic
Figure 7 AAMP Blockade Reduces Wire-Induced NI Formation
(A) Mice intraperitoneally treated with nonimmune serum developed normal neoin
significantly reduced. (B) Histomorphometrical assessment revealed a marked red
areas did not differ. (C and D) One week after anti-rAAMP-ab treatment, neointima
4 weeks, anti-rAAMP-ab treatment did not reduce neointimal SMC density compare
liferation indexes (percent Ki67-positive nuclei) in the neointima (NI) at 1 and 4 weesions in the smaller mouse carotid arteries as well as the aechanisms of applied mechanical injury vary significantly
etween rodents and the situation in humans.
Although prior studies supported a relevance of AAMP for
ellular migration in angiogenesis and cancerogenesis, only
imited data regarding the mechanistic role of AAMP are
vailable. Here, it could be demonstrated that AAMP is
ocalized on the cellular membrane and in the cytosol of SMCs
MC Density in ApoE/ Mice
yperplasia, whereas in the anti-rAAMP-ab–treated group, neointimal area was
of neointimal hyperplasia in the anti-rAAMP-ab–treated group, whereas medial
density represented by -SMA staining was reduced compared with control. After
nonimmune serum. (E) Vascular cell proliferation analysis revealed similar pro-
fter injury in both groups. Abbreviations as in Figures 2 and 6.and S
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July 22, 2008:302–11 AAMP and Accelerated Atherosclerosisecisive for the regulation of SMC migration. Thus, a block-
de of membranous AAMP by an inhibitory antibody or by
ownregulation of AAMP decreases SMC migration and,
oncomitantly, results in a decreased activity of the small
TPase RhoA, which is known to play a key role for control
f cellular migration (6,22). Computed protein structure anal-
sis revealed a potential transmembrane domain between
mino acids 322 and 345 and thereby supports the significance
f AAMP as a membrane-associated protein. Because homol-
gy analysis shows that AAMP shares sequence homology
ith immunoglobulin superfamily members like cellular adhe-
ion molecules NCAM, PECAM, and LFA-2, which are
nown to mediate adhesion and migration of various malig-
ant circulating cells (1), a potential binding of AAMP to
eparin or to beta-actinin was suggested. Applying advanced
maging and cell fractioning techniques, this study could clearly
emonstrate that AAMP is localized in the cellular membrane
nd regulates SMC migration via the RhoA pathway.
igure 8 summarizes these findings schematically. Due to
ur data, AAMP can also be found in the cytosol but a
unctional role for the regulation of cell migration could not
e attributed to cytosolic AAMP. Furthermore, secreted
AMP to the extracellular area as suggested previously
ould not be detected.
In summary, we have identified AAMP, abundantly
roduced by neointimal SMCs after vascular injury, as a
otential regulator of SMC migration in atherosclerotic and
estenotic disease.
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Figure 8 Regulation of SMC Migration by AAMP
Abbreviations as in Figure 2. Figure illustration by Rob Flewell.2074 Aachen, Germany. E-mail: rblindt@ukaachen.de.
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APPENDIX
or supplementary material regarding the culture of smooth muscle cells,
lease see the online version of this article.
